The Life Sciences team advised CRISPR Therapeutics AG (Nasdaq: CRSP) on its underwritten public offering, including the full exercise of the underwriters’ option to purchase additional shares, of an aggregate of 7,392,857 common shares at a price to the public of $70.00 per share. Aggregate gross proceeds were approximately $517.5 million, before deducting underwriting discounts and commissions and estimated offering expenses.
CRISPR is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
The Goodwin team was led by Rob Puopolo and included Dan Karelitz and Ettore Santucci.
For more details, read the press release and articles in Reuters, Labiotech.eu, and Endpoints.
CRISPR is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
The Goodwin team was led by Rob Puopolo and included Dan Karelitz and Ettore Santucci.
For more details, read the press release and articles in Reuters, Labiotech.eu, and Endpoints.